Humacyte, Inc. (NASDAQ:HUMA) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Humacyte, Inc. (NASDAQ:HUMA) have earned a consensus rating of “Moderate Buy” from the eight analysts that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $6.1071.

HUMA has been the subject of several recent analyst reports. Wall Street Zen lowered shares of Humacyte from a “sell” rating to a “strong sell” rating in a research note on Saturday. D. Boral Capital reissued a “buy” rating and set a $25.00 price target on shares of Humacyte in a research report on Tuesday, April 28th. TD Cowen cut their price target on shares of Humacyte from $1.50 to $1.25 and set a “buy” rating on the stock in a report on Wednesday, June 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Humacyte in a research report on Wednesday, July 8th. Finally, Benchmark reduced their price objective on shares of Humacyte from $2.00 to $1.00 and set a “speculative buy” rating for the company in a research report on Thursday, August 13th.

Hedge Funds Weigh In On Humacyte

A number of hedge funds and other institutional investors have recently modified their holdings of HUMA. UBS Group AG increased its position in shares of Humacyte by 48.8% during the fourth quarter. UBS Group AG now owns 2,978,610 shares of the company’s stock valued at $2,862,000 after acquiring an additional 976,275 shares during the last quarter. R Squared Ltd purchased a new position in Humacyte in the fourth quarter worth $25,000. SG Americas Securities LLC boosted its position in Humacyte by 50.3% in the fourth quarter. SG Americas Securities LLC now owns 34,075 shares of the company’s stock worth $33,000 after purchasing an additional 11,411 shares during the last quarter. Stonepine Capital Management LLC bought a new position in Humacyte in the 2nd quarter valued at $180,506,000. Finally, LaSalle St. Investment Advisors LLC bought a new position in Humacyte in the 2nd quarter valued at $89,000. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Humacyte Trading Down 7.3%

Shares of Humacyte stock opened at $0.56 on Tuesday. The stock has a fifty day simple moving average of $0.76 and a 200 day simple moving average of $0.90. Humacyte has a 12-month low of $0.53 and a 12-month high of $2.55. The company has a market capitalization of $151.16 million, a P/E ratio of -1.14 and a beta of 2.54. The company has a current ratio of 6.21, a quick ratio of 5.74 and a debt-to-equity ratio of 2.07.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.05). Humacyte had a negative net margin of 4,556.29% and a negative return on equity of 983.32%. The company had revenue of $0.41 million during the quarter, compared to analysts’ expectations of $1.04 million. On average, sell-side analysts anticipate that Humacyte will post -0.38 earnings per share for the current fiscal year.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.